Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study

Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, James M. Foran, Vikas Gupta, Gary J. Schiller, Don Ambrose Stevens, Moshe Talpaz, Sarah Wall, Terra L. Lasho, Abhishek A. Mangaonkar, Talha Badar, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju, Guillermo Garcia-Manero

Blood Neoplasia (2025) 2 (4): 100115.

https://doi.org/10.1016/j.bneo.2025.100115

Published: 2025

Includes: Supplemental data

Journal Articles

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Vinod A. Pullarkat, Mark Levis, James McCloskey, Gabriel N. Mannis, Stephen A. Strickland, Amir T. Fathi, Tara L. Lin, Vijaya R. Bhatt, Thuva Vanniyasingam, Divya Chakravarthy, Yana Lutska, Stefan Faderl, Ronald S. Cheung, Harry P. Erba

Blood Neoplasia (2025) 2 (4): 100123.

https://doi.org/10.1016/j.bneo.2025.100123

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

Adam Y. Lin, Jonathan S. Rink, Eva Yang, Sara Small, Jessica J. Gerber, Taylor J. Zak, Jessica Altman, Yasmin Abaza, Leonidas C. Platanias, Leo I. Gordon, C. Shad Thaxton

Blood Neoplasia (2025) 2 (4): 100122.

https://doi.org/10.1016/j.bneo.2025.100122

Published: 2025

Includes: Supplemental data

Journal Articles

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens

Shannalee Martinez, Vladimir V. Senyukov, Suheyla Hasgur, Arianexys Aquino-López, Peter D. Emanuel, Y. Lucy Liu, Elliot Stieglitz, Gregory Behbehani, Amanda R. Campbell, Dean A. Lee

Blood Neoplasia (2025) 2 (4): 100135.

https://doi.org/10.1016/j.bneo.2025.100135

Published: 2025

Includes: Supplemental data

Journal Articles

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo, Amy E DeZern, Gabriel Ghiaur, Lukasz P Gondek, William Brian Dalton, Theodoros Karantanos, Tania Jain, Gabrielle T Prince, Richard J Jones, B. Douglas Smith, Alexander J Ambinder

Blood Neoplasia (2025) 2 (4): 100133.

https://doi.org/10.1016/j.bneo.2025.100133

Published: 2025

Includes: Supplemental data

Journal Articles

Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?

Noel F. T. Fong, David M. Ross, David T. Yeung, Timothy P. Hughes, Naranie Shanmuganathan

Blood Neoplasia (2025) 2 (4): 100138.

https://doi.org/10.1016/j.bneo.2025.100138

Published: 2025

Journal Articles

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia (2025) 2 (4): 100145.

https://doi.org/10.1016/j.bneo.2025.100145

Published: 2025

Journal Articles

Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis

Fang Zhou, Biljana Culjkovic-Kraljacic, Christian Bach, Li Feng, Yuta Mishima, Katherine L. B. Borden, Daniel G. Tenen

Blood Neoplasia (2025) 2 (4): 100132.

https://doi.org/10.1016/j.bneo.2025.100132

Published: 2025

Includes: Supplemental data

Journal Articles

SRSF2 mutations in CCUS, MDS and AML: a cross-entity study

Sandra Huber, Sarah Ochmann, Stephan Hutter, Veronika Ecker, Manja Meggendorfer, Gregor Hoermann, Torsten Haferlach, Claudia Haferlach, Isolde Summerer

Blood Neoplasia (2025) 2 (4): 100144.

https://doi.org/10.1016/j.bneo.2025.100144

Published: 2025

Includes: Supplemental data

Journal Articles

Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML

Fieke W. Hoff, Ashley O. Yocum, Uma M. Borate, Alice S. Mims, John C. Byrd, Yazan F. Madanat

Blood Neoplasia (2025) 2 (3): 100125.

https://doi.org/10.1016/j.bneo.2025.100125

Published: 2025

Includes: Supplemental data

Journal Articles

Elevated B 12 serum levels are associated with the presence of clonal hematopoiesis

Varun Gupta, Peter D. Lyon, Aristeidis G. Telonis, Marina Konopleva, Luisa Cimmino

Blood Neoplasia (2025) 2 (3): 100136.

https://doi.org/10.1016/j.bneo.2025.100136

Published: 2025

Includes: Supplemental data

Journal Articles

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Suravi Raychaudhuri, Megan Othus, Mary-Elizabeth M. Percival, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, Jacob S. Appelbaum

Blood Neoplasia (2025) 2 (3): 100129.

https://doi.org/10.1016/j.bneo.2025.100129

Published: 2025

Journal Articles

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Zhihong Zeng, Kala Hayes, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Shuko Nojiri, Yasushi Okazaki, Michael Andreeff, Marina Konopleva, Yoko Tabe

Blood Neoplasia (2025) 2 (3): 100121.

https://doi.org/10.1016/j.bneo.2025.100121

Published: 2025

Includes: Supplemental data

Journal Articles

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Rose Laflamme, Véronique Lisi, Josée Hébert, Guy Sauvageau, Sébastien Lemieux, Vincent-Philippe Lavallée, Guillaume Lettre

Blood Neoplasia (2025) 2 (3): 100118.

https://doi.org/10.1016/j.bneo.2025.100118

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Mengdan Liu, Ming Yan, Amanda G. Davis, Samuel A. Stoner, Edward D. Ball, Dong-Er Zhang

Blood Neoplasia (2025) 2 (3): 100107.

https://doi.org/10.1016/j.bneo.2025.100107

Published: 2025

Includes: Supplemental data

Journal Articles

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids

Blood Neoplasia (2025) 2 (3): 100108.

https://doi.org/10.1016/j.bneo.2025.100108

Published: 2025

Includes: Supplemental data

Journal Articles

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Elias Lagonik, Elyse C. Page, John B. Bruning, Laura N. Eadie, Susan L. Heatley, Matthew Greenwood, Chun Y. Fong, Andrew S. Moore, David T. Yeung, Timothy P. Hughes, Deborah L. White

Blood Neoplasia (2025) 2 (3): 100109.

https://doi.org/10.1016/j.bneo.2025.100109

Published: 2025

Includes: Supplemental data

Journal Articles

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study

Mingfei Yan, Robert Stuver, Kai Shiang Lin, William T. Johnson, Steven M. Horwitz, Ahmet Dogan, Wenbin Xiao

Blood Neoplasia (2025) 2 (3): 100112.

https://doi.org/10.1016/j.bneo.2025.100112

Published: 2025

Includes: Supplemental data

Journal Articles

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

Malin Sveijer, Désirée Gavhed, Helena Hertzberg, Eric Zander, Jan-Inge Henter, Tatiana von Bahr Greenwood

Blood Neoplasia (2025) 2 (3): 100098.

https://doi.org/10.1016/j.bneo.2025.100098

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival

Blood Neoplasia (2025) 2 (3): 100085.

https://doi.org/10.1016/j.bneo.2025.100085

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis

SRSF2 mutations in CCUS, MDS and AML: a cross-entity study

Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML

Elevated B 12 serum levels are associated with the presence of clonal hematopoiesis

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only